Transarterial chemoembolization alone or followed by bevacizumab for treatment of colorectal liver metastases
| Autor: | Donatella Sarti, Alberto Rebonato, Stefano Guadagni, Camillo Aliberti, Riccardo Inchingolo, Caterina Fiorentini, Giammaria Fiorentini, Roberto Nani, Massimiliano Nestola, Michele Nardella |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Bevacizumab Angiogenesis Colorectal cancer polyethylene glycol microspheres angiogenesis bevacizumab colorectal carcinoma DC beads radiopaque irinotecan liver metastases transarterial chemoembolization Tumor response medicine.disease_cause Gastroenterology 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Mutational status Hepatology business.industry Cancer medicine.disease Irinotecan Oncology 030220 oncology & carcinogenesis KRAS business medicine.drug Research Article |
| Zdroj: | Hepatic Oncology |
| ISSN: | 2045-0931 2045-0923 |
| Popis: | Aims: Bevacizumab (B) in association with systemic chemotherapy is commonly used for the treatment of colorectal cancer liver metastases. The aim of this study was to monitor tumor response, overall survival (OS) and progression-free survival (PFS) of patients with colorectal cancer liver metastases treated with transarterial chemoembolization (TACE) + B compared with TACE alone and to correlate the results with KRAS mutational status. Patients & methods: This was an observational multicentric case–control study (NCT03732235) on the efficacy and safety of B administered after TACE. Results: The disease control rate was significantly higher for the TACE + B than the TACE alone group (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|